Summary
Abbott Laboratories filed its 2013 10-K on February 20, 2014, reporting on its business and financial performance for the fiscal year ended December 31, 2013. A significant event for the company was the January 1, 2013 separation of its research-based pharmaceuticals business into an independent entity, AbbVie Inc. This separation resulted in the proprietary pharmaceutical products segment being presented as discontinued operations, allowing Abbott to focus on its diversified healthcare products. The company's remaining segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Financially, Abbott demonstrated resilience, with net sales showing an increase. The company highlighted growth in its Nutritional and Diagnostic segments, driven by demographic trends and new product introductions. However, the Established Pharmaceutical Products segment faced macroeconomic and market pressures, particularly in emerging markets, while the Vascular Products segment experienced pricing pressure and a decline in U.S. market due to competition and market conditions. The company also addressed its ongoing commitment to research and development, investing significantly to drive future innovation across its business segments.
Financial Highlights
55 data points| Revenue | $19.66B |
| Cost of Revenue | $9.19B |
| Gross Profit | $10.46B |
| SG&A Expenses | $6.37B |
| Operating Expenses | $17.52B |
| Operating Income | $2.13B |
| Interest Expense | $145.00M |
| Net Income | $2.58B |
| EPS (Basic) | $1.64 |
| EPS (Diluted) | $1.62 |
| Shares Outstanding (Basic) | 1.56B |
| Shares Outstanding (Diluted) | 1.57B |
Key Highlights
- 1Abbott completed the separation of its research-based pharmaceutical business (AbbVie Inc.) on January 1, 2013, refocusing on diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
- 2Net sales increased to $21.8 billion in 2013 from $21.5 billion in 2012, reflecting growth driven by the Nutritional and Diagnostic segments.
- 3The Nutritional Products segment saw sales growth of 4.3% (excluding foreign exchange), benefiting from demographic trends and new product introductions, although a product recall in China impacted performance in the latter half of the year.
- 4The Diagnostic Products segment reported a 5.9% increase in sales (excluding foreign exchange), driven by unit growth across geographical regions and continued execution of integrated solutions for healthcare customers.
- 5The Established Pharmaceutical Products segment faced challenges with a 2.9% decrease in sales (excluding foreign exchange), largely due to market pressures in emerging markets and austerity measures in developed markets.
- 6The Vascular Products segment saw a 1.9% decrease in sales (excluding foreign exchange), impacted by pricing pressure on drug-eluting stents and a decline in U.S. market procedures.
- 7Abbott spent approximately $1.5 billion on research and development in 2013, underscoring its commitment to innovation across its core segments.